Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$0.83 USD
-0.08 (-9.10%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $0.88 +0.05 (5.77%) 5:32 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Seres Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -113.72 | -250.16 | -65.58 | -89.13 | -70.28 |
Depreciation/Amortization & Depletion | 7.15 | 8.02 | 8.97 | 7.58 | 7.43 |
Net Change from Assets/Liabilities | -58.98 | -18.39 | 41.53 | -23.20 | -24.63 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 48.20 | 31.71 | 21.77 | 11.14 | 10.96 |
Net Cash From Operating Activities | -117.35 | -228.82 | 6.69 | -93.61 | -76.52 |
Property & Equipment | -7.98 | -9.82 | -9.57 | -0.59 | -1.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 18.56 | 92.25 | 73.65 | -158.30 | -29.52 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 10.58 | 82.43 | 64.09 | -158.89 | -30.52 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 21.19 | 103.90 | 2.13 | 283.52 | 61.66 |
Issuance (Repayment) of Debt | 50.52 | 25.70 | -0.95 | 0.00 | 25.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 19.90 | -0.43 |
Net Cash from Financing Activities | 71.71 | 129.60 | 1.18 | 303.42 | 86.23 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -35.07 | -16.79 | 71.95 | 50.92 | -20.81 |
Cash at Beginning of Period | 171.22 | 188.00 | 116.05 | 65.13 | 85.93 |
Cash at End of Period | 136.15 | 171.22 | 188.00 | 116.05 | 65.13 |
Diluted Net EPS | -0.89 | -2.31 | -0.72 | -1.12 | -1.24 |
Fiscal Year End for Seres Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -73.00 | -40.13 | -113.72 | -72.48 | -24.62 |
Depreciation/Amortization & Depletion | 3.93 | 2.02 | 7.15 | 5.11 | 3.03 |
Net Change from Assets/Liabilities | -25.79 | -9.15 | -58.98 | -43.59 | -20.80 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 19.82 | 12.03 | 48.20 | 41.10 | 31.80 |
Net Cash From Operating Activities | -75.05 | -35.24 | -117.35 | -69.86 | -10.60 |
Property & Equipment | -0.16 | -0.06 | -7.98 | -7.10 | -5.30 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 18.56 | 18.56 | 18.56 |
Other Investing Activities | 1.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 1.24 | -0.06 | 10.58 | 11.46 | 13.26 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 18.76 | 18.76 | 21.19 | 14.76 | 13.32 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 50.52 | 50.52 | 50.52 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 18.76 | 18.76 | 71.71 | 65.28 | 63.83 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -55.05 | -16.54 | -35.07 | 6.88 | 66.49 |
Cash at Beginning of Period | 136.15 | 136.15 | 171.22 | 171.22 | 171.22 |
Cash at End of Period | 81.11 | 119.61 | 136.15 | 178.10 | 237.71 |
Diluted Net EPS | -0.22 | -0.27 | -0.31 | -0.37 | 0.36 |